Nyxoah SA Ordinary Shares (NYXH) is a publicly traded Healthcare sector company. As of July 8, 2026, NYXH trades at $1.70 with a market cap of $177.13M and a P/E ratio of 0.00. NYXH moved -5.93% today. Year to date, NYXH is -63.87%; over the trailing twelve months it is -78.63%. Its 52-week range spans $1.26 to $11.87. Analyst consensus is buy with an average price target of $5.00. Rallies surfaces NYXH's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Nyxoah Q2 Sales Climb 21% to €7.7M, CMS Proposes 12%–15% Reimbursement Hike: Nyxoah reports preliminary Q2 net revenue of €7.7 million, up 21% sequentially, driven by 22% U.S. sales growth to €5.2 million, activation of 89 new high-volume accounts (total 180) and training of 55 new surgeons. CMS proposed boosting Genio procedure reimbursement by 12% in hospitals and 15% in surgical centers, while the company secured €110 million financing and held €97.8 million cash.
| Metric | Value |
|---|---|
| Price | $1.70 |
| Market Cap | $177.13M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $11.87 |
| 52-Week Low | $1.26 |
| Volume | 331.94K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
3 analysts cover NYXH: 0 strong buy, 1 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $5.00.